Mass spectrometry-based "omics" technologies for the study of gestational diabetes and the discovery of new biomarkers

Mass Spectrom Rev. 2023 Jul-Aug;42(4):1424-1461. doi: 10.1002/mas.21777. Epub 2022 Apr 27.

Abstract

Gestational diabetes (GDM) is one of the most common complications occurring during pregnancy. Diagnosis is performed by oral glucose tolerance test, but harmonized testing methods and thresholds are still lacking worldwide. Short-term and long-term effects include obesity, type 2 diabetes, and increased risk of cardiovascular disease. The identification and validation of sensitidve, selective, and robust biomarkers for early diagnosis during the first trimester of pregnancy are required, as well as for the prediction of possible adverse outcomes after birth. Mass spectrometry (MS)-based omics technologies are nowadays the method of choice to characterize various pathologies at a molecular level. Proteomics and metabolomics of GDM were widely investigated in the last 10 years, and various proteins and metabolites were proposed as possible biomarkers. Metallomics of GDM was also reported, but studies are limited in number. The present review focuses on the description of the different analytical methods and MS-based instrumental platforms applied to GDM-related omics studies. Preparation procedures for various biological specimens are described and results are briefly summarized. Generally, only preliminary findings are reported by current studies and further efforts are required to determine definitive GDM biomarkers.

Keywords: gestational diabetes mellitus; mass spectrometry; metabolomics; metallomics; proteomics.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes, Gestational* / diagnosis
  • Female
  • Glucose Tolerance Test
  • Humans
  • Mass Spectrometry
  • Pregnancy

Substances

  • Biomarkers